key: cord-0995283-3qlk63ta
authors: Taramasso, Lucia; Di Biagio, Antonio; Mikulska, Malgorzata; Roberto Giacobbe, Daniele; Vena, Antonio; Dentone, Chiara; De Maria, Andrea; Delfino, Emanuele; Berruti, Marco; Russo, Chiara; Orsi, Andrea; Bruzzone, Bianca; Bassetti, Matteo
title: High doses of hydroxychloroquine do not affect viral clearance in patients with SARS‐CoV‐2 infection
date: 2020-07-23
journal: Eur J Clin Invest
DOI: 10.1111/eci.13358
sha: 7cbffd4678382bbbb49d53872cb0ae9d42ed8fbe
doc_id: 995283
cord_uid: 3qlk63ta

The use of hydroxychloroquine (HCQ) has been considered a therapeutic option by international guidelines and expert opinions during the first phase of COVID‐19 pandemics, (1‐10) although scientific evidence remained too scarce to make a definitive recommendation (11). While HCQ use has now been questioned by recent data (7), some previous works draw attention to contrasting results on enhanced viral clearance after HCQ treatment (1‐6,10).

The use of hydroxychloroquine (HCQ) has been considered a therapeutic option by international guidelines and expert opinions during the first phase of COVID-19 pandemics, 1-10 although scientific evidence remained too scarce to make a definitive recommendation 11 . While HCQ use has now been questioned by recent data 7 , some previous works draw attention to contrasting results on enhanced viral clearance after HCQ treatment [1] [2] [3] [4] [5] [6] 10 . In our hospital, we started using high dose of HCQ at the beginning of the epidemics, associated with tocilizumab and/or methylprednisolone in case of severe pneumonia. In this context, we analysed the data on the rate of nasal swab clearance of SARS-CoV-2, 7 days after HCQ initiation.

All consecutive patients diagnosed with confirmed SARS-CoV-2 and respiratory symptoms admitted to IRCCS Policlinico San Martino Hospital from 9 March 2020 to 29 March 2020 were enrolled in the present prospective observational study. All enrolled patients gave their consent for off-label HCQ use and for inclusion in the study. Diagnosis of SARS-CoV-2 was made on the basis of a positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay performed on nasal swabs at the time of hospitalization. HCQ was administered at the dose of 400 mg q12 h for 5 to 20 days, based on clinicians' judgment of clinical improvement. Laboratory and clinical data, including time of symptoms onset before HCQ administration were collected. The primary endpoint was viral clearance at day 7(±2 days), defined as the achievement of the first negative RT-PCR for SARS-CoV-2 at nasal swab. The secondary endpoints were viral clearance at day 10 and median time from symptom onset to viral clearance. We described categorical data as percentages and continuous data as median and range. Nonparametric comparative test for continuous data and χ 2 test for categorical data were used to compare variables between groups.

This article is protected by copyright. All rights reserved P<0.05 was considered statistically significant. The study was conducted in accordance with the International Conference on Harmonization guidelines, applicable regulations, and the principles of the Declaration of Helsinki. The study protocol has been approved by the Ligurian Ethical Committee on March 2020.

Out of 140 patients included in the study at the time of writing (19 April 2020), 97 had an available nasal swab seven days after initiation of HCQ treatment. Twenty-four (25%) were respectively, p=0.25). Among 56 patients who had an available nasal swab ten days after initiation of HCQ, 12 were negative (21%) and 44 still positive (79%). Of the six patients treated with azithromycin, 2 had negative nasal swab at day 7. Moreover, at 7-day evaluation, we found that the median time from symptom onset was longer in people who cleared the virus (15 days, range 10-31) than in people who did not (13 days, range 6-21), p=0.024.

These findings suggest that the time from symptoms onset, and not that from HCQ initiation, is an important driver of viral clearance. In our study, the exposure to high doses of HCQ did not bring benefits on viral clearance. Stopping the viral shedding could be considered as an important outcome in terms of global health, although not yet clearly related with a clinical outcome in patients with COVID-19. Indeed, it is reasonable to think that patients who clear SARS-CoV-2 stop to be contagious for other people, and all international consensus are based on this assumption to allow the hospital discharge or discontinuation of quarantine 11 . Then, finding

This article is protected by copyright. All rights reserved a drug capable of guaranteeing 7-day viral clearance would be of pivotal importance for stopping the cycle of viral transmission in the general population. However, according to our data, HCQ did not allow to achieve this important outcome in a high proportion of patients, even if given at a higher dosage than previously reported 3, 5 . The study is limited by the fact that we do not have a control group and thus we cannot exclude that the viral shedding could be even longer without HCQ treatment. Additionally, because of the discomfort associated with collection of consecutive nasopharyngeal swabs, we did not perform a daily collection of specimens; as a consequence, we were not able to estimate the overall median duration of viral shedding. Also, we did not analyze viral load. Moreover, the study was conducted in patients treated with steroids or tocilizumab in association to HCQ and we cannot exclude that the immunosuppression given by these drugs might have slowed down the time to viral clearance. However, most patients hospitalized with severe forms of COVID-19 require immune modulatory treatment and thus data collected in this population likely reflect those of hospitalized patients in real life context. With these limitations, in our study, a relevant proportion of patients with COVID-19 did not achieve rapid viral clearance after 7-day course of high dose of HCQ treatment.

Lucia Taramasso, Antonio Di Biagio had the idea for and designed the study and had full access to all data. Malgorzata Mikulska, Antonio Vena, Marco Berruti and Chiara Russo take responsibility for the integrity of the data and the accuracy of the data analysis. Lucia Taramasso , Antonio Di Biagio, Malgorzata Mikulska, Daniele Roberto Giacobbe, Antonio Vena, Chiara Dentone, Andrea De Maria, Marco Berruti and Chiara Russo contributed to writing of the report. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Médecine et Maladies Infectieuses

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

We want to acknowledge all the members of GECOVID-19 Study group

Authors have no conflict of interest to declare. This article is protected by copyright. All rights reserved